Merck's Q1 Financial Overview

Merck & Co., Inc. has announced a 2% year-on-year decline in its first-quarter sales for fiscal 2025, totaling $15.5 billion. Despite this, the company saw a 7% increase in net income, reaching $5.1 billion, and a similar rise in diluted earnings per share (EPS) to $2.01.

Leadership's Perspective

"Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline," stated Chairman and CEO Robert M. Davis. He emphasized the company's commitment to innovation and value creation for stakeholders.

Market Reaction

Following the announcement, Merck's stock experienced a 0.98% increase in premarket trading, reaching $79.51 per share at 6:38 am ET.